RXC006
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 18, 2021 (NCT05134727)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
PORCN inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05955183 | Phase 1 | Jul 27, 2023 | AstraZeneca |
| NCT05644600 | Phase 1 | Jan 10, 2023 | AstraZeneca, Parexel |
| NCT05134727 | Phase 1 | Nov 18, 2021 | AstraZeneca |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 3 | 3 | 1 | 2021 |
| Parexel | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1